Good outlook for Novozymes after eventful 2013

Strong increase in sales of products for the manufacture of pharmaceuticals

Danish enzymes producer Novozymes expects strong sales and earnings in 2014, after what Peder Holk Nielsen, President and CEO, described as an 'eventful 2013'.

Organic sales growth in 2013 was up 7% to DKK11.7bn (US$2.14bn), EBIT grew by 6% to DKK2.9bn and net profit by 9% to DKK2.2bn.

Sales to the Technical & Pharma Industries increased by 7% to DKK757m, driven by a strong increase in sales for the manufacture of pharmaceutical products, particularly in Europe, the Middle East and Africa.

Holk Nielsen said: 'We delivered a good finish to the year and ended at the high end of our guided ranges for sales growth and above that for earnings. The outlook for 2014 is positive. We expect that our diversified growth platform will enable us to deliver good sales and EBIT growth.'

Companies